RSV: The “Respiratory Killer” Lurking Among Us When discussing respiratory viruses, people are often more familiar with influenza or COVID-19, but RSV (Respiratory Syncytial Virus) is actually a hidden “health threat,” particularlyRead More…
GSK announced that its respiratory syncytial virus (RSV) vaccine Arexvy (RSVPreF3 OA/GSK3844766A) has been approved by the FDA for the prevention of lower respiratory disease (RSV-LRTD) caused by RSV infection in theRead More…
Recently, the US Food and Drug Administration (FDA) has granted respiratory syncytial virus (RSV) bivalent pre-fused F subunit vaccine (RSVpreF) breakthrough therapy recognition (BTD), which is an active immunization for the pregnantRead More…
Respiratory syncytial virus (RSV) is the most common pathogen of viral pneumonia in children, which occurs mostly in newborns and infants less than 6 months old, as well as in immunodeficiency patientsRead More…
Janssen Pharmaceutical recently announced that the US Food and Drug Administration (FDA) has awarded the company the breakthrough drug qualification (BTD) for prophylactic RSV advanced vaccines. It is used to prevent lowerRead More…